TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05661409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated.
Study: NCT06654739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser therapy + physiotherapy/exercise protocol
Description: laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol (program includes kinesitherapy, range of motion (ROM) exercises, stretching, strengthening, and flexibility exercises) for 6 consecutive weeks, for a minimum of 2 sessions per week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser therapy + physiotherapy/exercise protocol
Description: sham laser therapy + standard of care (SOC) represented by physiotherapy/exercise protocol (program includes kinesitherapy, range of motion (ROM) exercises, stretching, strengthening, and flexibility exercises) for 6 consecutive weeks, for a minimum of 2 sessions per week
Study: NCT06654713

Intervention type: OTHER
Intervention: Commercial AID system
Description: AID system that is commercially available and FDA approved for use

Intervention type: OTHER
Intervention: Open source AID system
Description: AID system that uses unregulated open-source software to customize an insulin delivery algorithm to connect an insulin pump to a continuous glucose monitor
Study: NCT05203913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The recommended dose for cisplatin is 20 mg per square meter administered as 60 minutes IV infusions every 7 days (weekly), during the radiotherapy period.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered over approximately 5 weeks.The total radiotherapy dose will be: 60 Gray in 25 fractions over 5 weeks on original bladder tumour, 50 Gray in 25 fractions over 5 weeks on whole bladder and pelvic nodes if included, administered as concomitant boost. Radiation therapy will be delivered once daily (Monday-Friday) continuously without a planned break for tumour response assessment during treatment.
Study: NCT04647734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 12 weeks of high intensity interval training on exercise bike for 38 minutes 3 times a week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: standard care after discharge from hospital (control group)
Study: NCT05043857

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Postoperative Stereotactic Body Radiation Therapy (SBRT) after tumor resection targeting 2 volumes~* CTV1 (clips+isotropic 5mm expansion, edited on anatomic barriers): receiving 40 Gy in 5 fractions of 8 Gy~* CTV2 (CTV1+ anisotropic 10-15 mm expansion including corresponding vessels, retroperitoneum posterior to the SMV/SMA or celiac axis, edited on anatomic barriers): receiving 30 Gy in 5 fractions of 6 Gy.
Study: NCT06317597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
Description: OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfate oral solution to 500ml and intake 12-14 hours before colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
Study: NCT06388031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Physician's choice immunotherapy with one of the following every 21 days until disease progression or intolerable toxicity or up to 17 cycles:~* Pembrolizumab 200mg;~* Tislelizumab 200mg;~* Camrelizumab 200mg;~* Toripalimab 240mg.
Study: NCT06462131

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cultural Adapted Group cognitive Behaviroal therapy (CaGCBT)
Description: In first session, introduction of the therapist/facilitator and group members will be made. Group rules will be discussed with members. Group members' introduction primarily focuses on participant/clients' expectations, addictive behaviors and its status, and goals. Moreover, it also emphasize on identification of any other significant issue that is contributing in burden of disease.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cultural Adapted Group cognitive Behaviroal therapy (CaGCBT)
Description: In first session, introduction of the therapist/facilitator and group members will be made. Group rules will be discussed with members. Group members' introduction primarily focuses on participant/clients' expectations, addictive behaviors and its status, and goals. Moreover, it also emphasize on identification of any other significant issue that is contributing in burden of disease.
Study: NCT05434351

Intervention type: OTHER
Intervention: vaginal dehydroepiandrosterone
Description: the clinical outcome in Chinese women with moderate to severe symptoms of GSM treated with vaginal DHEA for 12 weeks will be evaluated
Study: NCT05554172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Participants will receive vagal nerve stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants will receive sham stimulation approximately 3 days a week for 30 minutes over the course of 4 weeks while they are attending treatment for Anorexia Nervosa in the Eating and Weight Disorder Intensive Program.
Study: NCT04969354

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at CAIX antigen.
Study: NCT06397222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sin-Bev-SIRT
Description: Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study: NCT05306197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-Contingent Feedback Training
Description: Feedback according to participants' viewing patterns, in order to modify their attention toward threat stimuli.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: Attention training via repeated trials of a dot-probe task intended to direct attention toward threat stimuli using threat and neutral face stimuli.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Contingent Feedback Training
Description: Participants listen to a musical track they chose with no operant conditioning.
Study: NCT06215131

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person dietary weight loss counseling
Description: The counseling content will be 30 minutes of RDN delivered educational session on energy density and portion sizes then the second 30 minutes being the RDN answering participant questions and providing feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality dietary weight loss counseling
Description: The counseling content will be 30 minutes of virtual reality delivered educational session on energy density and portion sizes with an RDN remotely monitoring then the second 30 minutes being the RDN answering participant questions and providing feedback through synchronous audio/video.
Study: NCT05661409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is a FDA-approved drug that is in routine clinical use for NMB reversal.~Patients will be randomized to six groups: 2 mg/kg (the lowest dose approved by the FDA), 1 mg/kg, 0.5 mg/kg, 0.25 mg/kg, 0.125 mg/kg of sugammadex and placebo. Doses would be based on actual body weight. The time taken to reach a TOF ratio of 0.9 thereafter would be measured. If the patient fails to achieve this goal by 10 minutes, sugammadex would be given in 2 mg/kg increments until the patient reaches this threshold and can be safely extubated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be used as placebo. The inclusion of a placebo group would allow us to examine if patients may recover spontaneously over that time without needing any sugammadex at all, and what parameters may predict that subset of patients. It will also improve the dose response modelling, in that randomization has been weighted so that patients who are least likely to need sugammadex (i.e. if they achieved a TOF count of 4 twitches without fade) are more likely to be in the placebo group or at the lowest dose of sugammadex that is being tested.
Study: NCT05815173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: Ladarixin dose will be escalated as follows in Phase I: 3 patients will receive a starting dose of 200mg. If 2 or more patients experience a DLT at the lowest dose, the study will stop. If 0 out of 3 patients experience a DLT within 28 days, the next 3 patients will receive 300mg. If 1 out of 3 patients experiences a DLT, 3 more patients will be added to the 200 mg dose. If no more patients experience a DLT at 200mg, the next 3 patients will receive 300mg. If 2 of 6 patients receiving 200mg experience a DLT, the study will stop. If 2 or more patients experience DLTs, the maximum tolerated dose (MTD) will be the previous dose level. The same process will be repeated at each dose level. There will be 6 patients enrolled at MTD level for a maximum of 12 patients in the phase I cohort. Ladarixin will be administered as a twice-daily dose over a 21 day treatment cycle.~In Phase II, ladarixin will be administered twice-daily at the recommended phase II dose over 21-day cycles.
Study: NCT06558058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg film-coated tablet
Description: One tablet of the test drug was given orally after an overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xarelto 10 mg film-coated tablet
Description: One tablet of the reference drug was given orally after an overnight fast.
Study: NCT06317597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
Description: OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfates oral solution to 500ml and intake 16-18 hours before the colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
Study: NCT05034081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: body contouring
Description: any post-bariatric body contouring surgery included
Study: NCT05482204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Climate Impact label
Description: Menu labels indicating low climate impact on chicken, fish, and vegetarian food items on a simulated online fast food menu.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Climate Impact label
Description: Menu labels indicating high climate impact on beef food items on a simulated online fast food menu.
Study: NCT05270122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with ThrombX Retriever
Description: Revascularization
Study: NCT05604274

Intervention type: OTHER
Intervention: App to monitor stool consistency and symptoms
Description: App to monitor stool consistency and symptoms

Intervention type: OTHER
Intervention: App to monitor stool consistency and symptoms
Description: App to monitor stool consistency and symptoms

Intervention type: OTHER
Intervention: App to monitor stool consistency and symptoms
Description: App to monitor stool consistency and symptoms
Study: NCT06631066

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation
Description: Neoadjuvant chemoradiation will be prescribed as: 4 cycles of Adriamycin and Cyclophosphamide followed by radiotherapy concurrently with taxanes/ taxanes and carboplatin. followed by surgery as indicated.
Study: NCT06224894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antiemetic treatment
Description: antiemetic treatment
Study: NCT06541132

Intervention type: OTHER
Intervention: Observational study without human intervention
Description: Observational study without human intervention
Study: NCT04184206

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention training intervention 1
Description: 14-day smartphone-based audio-guided attention training program with heavy mindfulness component

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention training intervention 2
Description: 14-day smartphone-based audio-guided attention training program with moderate mindfulness component
Study: NCT05560113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: cTBS, a patterned form of TMS, (80% active motor threshold intensity, 3 pulses at 50Hz, 200ms interval, 600 pulses, 40s duration applied over the targeted sensory cortical region using real-time neuronavigation to focally and transiently inhibit neural activity
Study: NCT04184206

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention training intervention 3
Description: 14-day smartphone-based audio-guided attention training program without mindfulness component
Study: NCT05560113

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham continuous theta burst stimulation (cTBS)
Description: This will be a sham intervention. An active/sham stimulating coil will be used for double-blinding of stimulation condition. cTBS is safe and has established safety guidelines that will be strictly adhered to during study conduction.
Study: NCT05379530

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thromboelastography (TEG)
Description: Thromboelastography (TEG) is a type of Viscoelastic testing (ROTEM is another example) and is a validated point of care method of dynamically assessing intraoperative coagulopathy via functional assay.
Study: NCT05816200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-Level Light Therapy
Description: Punctual applications of infrared laser (L2) (power of 100mW, 808 nm, 6 joules of energy/60 seconds) in the affected region, keeping one centimeter of distance between the points, until the entire area of the complaint was irradiated. being held one session per week, totaling eight weeks of treatment at the end of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation
Description: Using a device at a frequency of 50 Hertz with intensity modulated according to the patient's comfort ranging from 1 - 4 (pulse amplitude) with a duration of 25 minutes per session, with one session per week, totaling eight weeks of treatment at the end of the study. The device's self-adhesive electrodes were fixed on the participant's face, following the path of the trigeminal nerve branch on the side affected by pain and/or burning.
Study: NCT05433259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight orthokeratology
Description: Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Overnight orthokeratology
Description: Subjects require to wear the lenses every night, with a recommended time of 6-8 hours.
Study: NCT05379530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthesia Provider Survey
Description: Pre-operative and post-operative provider surveys will be distributed to anesthesiologists caring for study subjects to assess knowledge, practice, and attitudes about TEG.
Study: NCT05482451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, an immune checkpoint inhibitors targeting PD-1, represents a popular treatment option for patients with cancers via immunological mechanism. However, previous studies using nivolumab alone in pancreatic cancer have failed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid
Description: Our previous basic studies revealed that all-trans retinoic acid repressed pancreatic adenocarcinoma cell growth and colony formation. All-trans retinoic acid represses ADAR1, a member of interferon-stimulated genes and a negative regulator of IFNs signaling. On the other hand, all-trans retinoic acid simultaneously increases PD-L1 expression for cancer cells to evade immune surveillance. Since combination of anti-PD1 antibody and all-trans retinoic acid may block self-regulating negative feedback loops of IFNs response, this therapeutic strategy may improve outcomes of pancreatic adenocarcinoma patients.
Study: NCT05894226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic ventral mesh rectopexy
Description: patients are treated by laparoscopic ventral mesh rectopexy for anterior rectocele
Study: NCT05593133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pnf exercises
Description: PNF techniques will comprise of Warm up, Rhythmic stabilization, Hold Relax, Contract Relax and light exercises and performed on three muscle groups ( Hamstring, Quad and Calf).~20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training exercises
Description: gait Training exercises comprised of one foot balancing, leg raises, heel raises, tight-rope walking. 20 participants will be followed up with the therapist regularly twice a week for 30 minutes session each for a duration of 8 weeks.
Study: NCT06318871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
Description: Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
Description: Autologous, cytokine induced memory-like natural killer cells, via intravenous (into the vein) infusion per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Description: Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity
Study: NCT05105919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg EC Tab
Description: Participants will receive a 7 day supply of Aspirin 80 mg EC Tab and will be instructed to take the drug at the same time every day for 7 days.
Study: NCT06467097

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT(Stereotatic Body Radiation Therapy)
Description: Patients will receive treatment for one to two weeks, one to five times per region.
Study: NCT05582109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab, Lenvatinib Combined With TACE
Description: PD-L1 inhibitor
Study: NCT04504903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy For Work Success (CBTw)
Description: Veterans will go to 12 weekly group sessions and will learn healthy thinking about work, positive behavioral coping related to work, and will form a work success plan based on their work goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Veterans will go to 12 weekly group sessions and will learn more information about their mental health conditions. Psychoeducation modules are from the Illness Management and Recovery program.
Study: NCT04191161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing the rigid brace
Description: Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wearing the rigid brace
Description: Custom braces are made from 4mm thick polyethylene with Velcro® fastening. They are Computer Aided Designed and are made by the same manufacturer (LAGARRIGUE). A thermal sensor chip will placed in the brace to assess observance.
Study: NCT06382506

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of Cornbread with Hazelnut Bread
Description: Cornbread was added to 15 grams and 30 grams of bread and consumed by the participants. Blood glucose levels were then measured. Obese and normal-weight individuals will be divided into two groups according to their anthropometric measurements.